CimCure was founded in 2016 as a spin-off from Prof. Arjan Griffioen’s Angiogenesis Laboratory at Amsterdam UMC, supported by the medical centre’s TTO Innovation Exchange Amsterdam. The company is led by Chief Scientific Officer, Arjan Griffioen, CEO, Diederik Engbersen, who both have extensive experience in the biotech industry. They started CimCure to design and develop a novel class of active cancer vaccines against all types of solid tumours at all stages.
The first financial means to start building the CimCure portfolio were provided in 2016 by the Dutch government and Amsterdam UMC in the form of proof-of-concept grants and pre-seed loans. With this financial input, the first product, CVx1, was tested in preclinical studies as well as in an efficacy study in client-owned dogs. The seed investment in CimCure was secured in July 2022, when a group of investors, led by Positron Ventures, ensured the financial means to test CimCure’s lead product in a phase 1 clinical study in patients.
CimCure has been housed at the Amsterdam UMC campus since 2016, where a fully equipped laboratory, and office spaces, were provided. In late autumn 2023 CimCure moved its HQ to a new location at the Health & Innovation District in Amsterdam.